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ABSTRACT 
Spinal muscular atrophy (SMA) is caused by the loss of a single gene, survival motor 
neuron-1 (SMN1), which results in the rapid deterioration of motor neuron integrity and function, 
most often leading to infantile death. Administration of self complementary adeno-associated 
virus expressing full-length SMN cDNA (scAAV-SMN) has proven an effective means to rescue 
the SMA phenotype in SMA mice, either by intravenous (IV) or intracerebroventricular (ICV) 
administration at very early time points. We have recently shown that ICV delivery of scAAV9-
SMN is more effective than a similar dose of vector administered via an IV injection, thereby 
providing an important mechanism to examine a timeline for ameliorating the disease and 
determining the optimal therapeutic window. SMNΔ7 mice were injected with scAAV9-SMN 
vector via ICV injection on a single day, from P2 through P8. At each delivery point from P2 
through P7, scAAV9-SMN decreased disease severity, ranging from a near complete rescue (P2) 
to a significant, albeit lesser degree (P7) in which animals lived ~130% longer. Our study 
demonstrates that a maximal benefit is obtained when treatment is delivered during a specified 
therapeutic window of the pre-symptomatic stages of SMA in the SMNΔ7 mouse model. 
Although disease severity can be significantly decreased when SMN levels are increased at later 
stages of the disease, there is a time (after postnatal day 8) at which therapy is no longer 
effective.
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CHAPTER ONE: INTRODUCTION TO SPINAL MUSCULAR ATROPHY 
Spinal Muscular Atrophy Overview 
The National Institute of Neurological Disorders and Stroke (NINDS) has classified over 
600 neurological disorders affecting millions of people worldwide (50 million in the USA alone), 
with an annual cost in hundreds of billions of dollars (National Institutes of Health website). 
Some of the more prevalent neurodegenerative diseases include Amyotrophic Lateral Sclerosis 
(ALS), Friedreich's Ataxia, Alzheimer's, Huntington's, Parkinson's, Lewy Body Disease, and 
Spinal Muscular Atrophy (SMA) (NINDS website). 
SMA is an autosomal recessive neurodegenerative disorder, and it is caused by the 
mutation of a single gene, survival motor neuron-1 (SMN1) [1], which codes for the ubiquitously 
expressed protein, SMN. Humans possess another nearly identical gene, SMN2, which can 
produce fully functioning SMN protein, but only at low levels. This is due to a C to T conversion 
within the 5′ end of exon 7 resulting in alternatively spliced SMN2-derived transcripts. SMA is a 
motor neuron disease and is characterized by the loss of α-motor neurons in the ventral horn of 
the spinal cord, which leads to muscle wasting, atrophy, paralysis and death in the more severe 
cases [1]. SMA is a common genetic cause of infantile death with an incidence of 1:6,000 – 
1:10,000 live births and a carrier frequency of 1 in 40 [2-5]. It is still unclear what critical 
function is disrupted by the severe reduction of SMN protein levels, but this leads to the 
pathogenesis of SMA. 
Strategies to circumvent SMA progression focus on SMN1 gene replacement or the 
alteration of SMN2 splicing [6]. Currently, there is no cure for SMA; and although clinical 
studies have shown that early intervention and nutritional support have positive outcomes for 
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SMA patients [7], SMA still remains absent from the required newborn screening panel. A pilot 
study is underway to assess the feasibility of prenatal screening for SMA in all newborns 
(Newborn Screening Translational Research Network at https://www.nbstrn.org). 
 
Spinal Muscular Atrophy Genetics 
SMA was first described by Werdnig and Hoffmann in the 1890s and became known as 
Werdnig-Hoffmann disease at that time, but today is synonymous with the most severe form of 
SMA. In their autopsy reports, Werdnig and Hoffmann described loss of α-motor neurons in the 
ventral horn of the spinal cord as well as atrophy of skeletal muscle [8]. It was not until 1995 that 
the SMA-determining gene was identified by Lefebvre et al. (Figure 1.1A) [1, 9]. Telomeric 
SMN1 and centromeric SMN2 are nearly identical and are positioned inversely from each other 
due to an early intrachromosomal duplication event, at the genomic region of 5q13 [1]. SMN1 
produces full-length transcript and functional SMN protein, but the alternatively spliced SMN2 
transcript produces approximately 90% truncated protein (Figure 1.1B and 1.1C) [10]. Although 
SMN1 and SMN2 are completely identical in amino acid sequence, there is a crucial 
translationally silent "C" to "T" transition located in exon 7 at position +6, which results in 
severe disruption of SMN2 splicing [11]. Importantly, SMN2 is a disease modifier because there 
is a strong inverse correlation between SMN2 copy number and disease severity, where higher 
SMN2 copy numbers result in a milder phenotype (Figure 1.2) [12, 13].
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Figure 1.1. Schematic representation of SMN1 and SMN2 at the DNA, RNA and protein level. 
A) SMN1 and SMN2 are located on Chromosome 5 in reverse order and differ by a single 
nucleotide in exon 7. B) SMN2 is alternatively spliced resulting in a greater abundance of 
transcripts lacking exon 7 (SMNΔ7). C) SMNΔ7 transcripts produce truncated, non-functional 
protein. 
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Figure 1.2. Circle graphs depicting SMA Type I, Type II and Type III patients and their 
corresponding SMN2 copy number. SMN2 is an important disease-modifying gene because each 
copy provides ~10% basal SMN levels which collectively, increases overall SMN protein levels 
with the addition of each SMN2 copy. Data adapted from [14]. 
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There are a few nucleotide differences between SMN1 and SMN2 but these do not alter 
protein structure [1, 11]. However, the C to T transition in exon 7 results in a functional 
difference between the two genes due to aberrant splicing of the SMN2 transcript [11]. Positive 
splicing regulators, such as SF2/ASF, are prevented from binding the region of exon 7, possibly 
due to the disruption of an exonic splice enhancer region [15] or from the creation of an exonic 
splice silencer region [16] following the single nucleotide change. Additionally, factors such as 
hnRNP-A1, which promote the exclusion of exon 7 [16], recruit negative regulators such as 
Element 1 [17] and ISS-N1 [18], which act as splicing repressors. This highly dynamic region in 
SMN2 leads to aberrant splicing ~90% of the time, generating a truncated transcript lacking exon 
7 (SMNΔ7) [1, 11, 19]. The SMNΔ7 protein cannot self-associate [20] or form complexes 
efficiently with RNAs and proteins [21], making it unstable, and thus it is rapidly degraded [22].  
 
SMN Protein Function  
SMN is a multifunctional protein known to bind many cellular proteins [23-26] and a few 
viral proteins [27-29]; and it is found in both the nucleus and cytoplasm of all cell types [30-32]. 
In the nucleus, SMN binds Gemin proteins forming aggregates called gems [12, 30, 31], which 
have been used as a cell biomarker because gem numbers correspond to overall SMN levels [23]. 
There are a multitude of cellular activities in which SMN is involved, however, the best 
understood function is the role SMN plays in snRNP biogenesis. SMN is crucial in 
transcriptional activation [23, 27, 33], translational regulation [23, 33, 34] stress response [23, 
33, 35, 36] and cell apoptosis [23, 37]. Furthermore, SMN functions in axonal RNA trafficking 
[23, 33, 38] and RNA splicing [23, 33, 39]. In the context of snRNP biogenesis and assembly, 
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SMN is essential [23, 33, 40] (Figure 1.3). Pre-mRNA splicing is mediated by the spliceosome, a 
complex of RNAs and RNA-binding proteins. In eukaryotic cells, these spliceosomal small 
nuclear ribonucleoproteins (snRNPs) are generated by a master assemblyosome [41], the SMN 
complex [23, 33, 40], before they organize into the final spliceosome machinery. snRNAs are 
transcribed in the nucleus and exported to the cytoplasm where the SMN complex (consisting of 
SMN and Gemins 2-8) [33] transfers Smith core proteins (Sm) onto the appropriate site of the 
snRNA [42]. The binding of Sm proteins onto the snRNAs is highly specific, and the SMN 
complex ensures this process is performed correctly [33, 42, 43]. Once the Sm cores have been 
assembled, the 3’ end of the snRNA processed, and the 5’ cap hypermethylated, the mature 
snRNP is imported into the nucleus by the SMN complex [44, 45] where it will associate with 
snRNP-specific proteins to generate the complete spliceosomal complex. When SMN levels are 
low, a decrease in Sm core assembly is observed which is correlated with SMA severity [33, 42]. 
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Figure 1.3. Diagram of SMN’s role in snRNP biogenesis. In the cytoplasm, the SMN complex 
assembles Sm proteins into a heptameric ring structure [23, 46]. Following transcription in the 
nucleus, snRNAs are transported to the cytoplasm where the SMN complex assembles the 
heptameric ring of Sm core proteins onto the specific binding site of the snRNA [33, 42, 43]. 
Following maturation, the SMN complex shuttles the snRNP into the nucleus where it will be 
assembled into the final spliceosomal complex [44, 45]. 
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Clinical Assessment of Spinal Muscular Atrophy 
SMA is classified into five subtypes according to disease severity and age of onset. 95% 
of SMA patients have a deletion in both copies of SMN1, while the remainder of the cases occur 
from frameshift, nonsense and missense mutations [47]. Type 0 SMA is embryonic lethality, and 
this occurs only if the fetus carries mutations in both the SMN1 and SMN2 genes. SMA Type I 
(Werdnig-Hoffmann disease) is the most severe clinical presentation of the disease and the most 
prevalent type among patients; 65% of all new cases and 80% of all current cases are Type I [7]. 
These patients present with symptoms before 6 months of age [48]; they have trouble eating and 
breathing and they never gain the strength to sit upright or crawl. Children with SMA Type I die 
by the age of two, usually from respiratory complications [7, 47, 48]. SMA Type II patients 
become symptomatic within 18 months [48], and are diagnosed once parents notice an extensive 
delay in motor control; for example the child may have trouble controlling head movements and 
may not move much or cannot sit upright. These patients are wheelchair bound and their life 
expectancy is variable, with 70% of patients living into adulthood [6]. Patients with Type III 
SMA, also known as Kugelberg-Welander disease, exhibit symptoms in adolescence and may 
eventually become wheelchair-bound [47] although they have a normal life expectancy [48]. 
Adult onset SMA, Type IV, is the mildest form of the disease and is characterized by mild 
muscle weakness usually after the age of 25 [47]. The clinical spectrum of SMA is broad and it 
may be difficult to classify an individual as having one type of SMA or another because often 
symptoms and disease characteristics overlap [48]. However, appropriate diagnosis and 
assessment of disease severity and progression are important in order to provide the patient with 
therapeutic intervention specifically tailored to their needs [7, 49]. 
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In 2006, Pyatt and Prior described a multiplex real-time PCR assay that identifies 
affected individuals and carriers with 100% sensitivity and specificity [50]. Then in 2008, SMA 
was nominated to be added to the federally mandated newborn screening panel [7]. The 
Secretary’s Advisory Committee on Heritable Diseases in Newborns and Children (SACHDNC) 
declined the proposal until further evidence could be collected through population-based 
screening to determine the efficacy and feasibility of screening all newborns for SMA. This 
population-based study is underway, involving several medical centers. Current studies are 
ongoing at the Department of Pediatrics at the University of Utah, School of Medicine and 
Colorado School of Public Health at the University of Colorado, coordinated under the Newborn 
Screening Translational Research Network (NBSTRN at https://www.nbstrn.org). 
 
Mouse Models of Spinal Muscular Atrophy 
Multiple mouse models have been generated to dissect the biological processes and 
pathogenesis of SMA and importantly, they are a powerful tool used to investigate preclinical 
therapeutics in a mammalian context. Models exhibiting disease phenotypes ranging from severe 
to intermediate have been created to mimic the pathology observed in Type I, and Type II and 
Type III patients, respectively. 
As with all species, except humans, mice have only a single Smn gene (equivalent of 
human SMN1) [51, 52] which results in embryonic lethality when lost or mutated [53]. In 2000, 
the first SMA mouse model (Smn-/-;SMN2+/+) was generated independently by two laboratories: 
FVB.Cg-Smn1tm1Hung Tg(SMN2)2HungSmn1tm1Hung 54/J (Jax 005058; [ ]) and FVB.Cg-
Tg(SMN2)89AhmbSmn1tm1Msd 55/J (Jax 005024; [ ]). Known as the severe “SMN2” model, this 
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transgenic mouse line was developed by inserting 2 copies of the human SMN2 transgene into 
the mouse Smn-null background (Smn-/- 53; [ ]). The low levels of SMN provided by the transgene 
were sufficient to rescue embryonic lethality however; this model is born symptomatic, with an 
average survival of 5 days and never reaches the same weight as unaffected littermates. 
A slightly less severe model (Smn-/-;SMN2+/+;SMNΔ7+/+) was later developed in 2005 by 
Le et al., with the addition of an SMN cDNA lacking exon7 (SMNΔ7) onto the background of 
the severe model (FVB.Cg-Tg(SMN2*delta7)4299AhmbTg(SMN2)89AhmbSmn1tm1Msd
56
/J; Jax 
005025) [ ]. As this work originated to investigate possible adverse effects incurred by the 
SMNΔ7 product, this group instead observed that this protein product associates with and 
stabilizes full-length SMN, as well as extends the survival to an average of 13 days. This model 
is termed the SMNΔ7 mouse model and it is born presymptomatic. This model has been the 
workhorse for many investigations in recent years because it becomes symptomatic during the 
early postnatal stage and lives relatively long enough to evaluate therapeutic intervention. 
As severe models are useful for evaluating the accelerated progression of SMA Type I, it 
is imperative to have intermediate models with a milder disease phenotype available to study the 
less severe pathogenesis of Types II and III SMA [6]. Therefore, intermediate models have been 
generated that exhibit a milder disease progression for which subtle differences, once masked by 
severe pathology, can now be brought to light; as well as, new therapeutics formulated that are 
more appropriate for Type II and III patients. 
Our lab recently generated an intermediate model for SMA called the Read through 
model SMNRT (SMN2+/+;SMNRT;Smn-/- 57) [ ].  This mouse line has the same genetics as the 
SMNΔ7 model, however, the Δ7 transgene is manipulated to produce a more stable isoform than 
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SMNΔ7 [58], called SMN read through. This model demonstrates a moderate disease severity 
and these mice live an average lifespan of 30 days. 
Another intermediate SMA mouse model, called the Smn2B/-
59
 model, has also been used 
for SMA research [ ]. These mice possess 15% of normal SMN protein levels and they become 
symptomatic around postnatal day 10. Smn2B/- 
 
mice live an average lifespan of 28 days. 
Intermediate mouse models are advantageous for extracting subtle biological information that 
may be overlooked by the overt disease phenotype of the severe models. Furthermore, use of 
these intermediate models will aid in the development of SMN2-independent therapies. 
Therapeutic Intervention in SMA     
Therapeutics aimed to attenuate SMA disease progression have encompassed various 
strategies ranging from those that focus on gene therapy or boosting SMN2 productivity, to those 
that use small molecular compounds to augment pathology through secondary pathways [6].  
Many treatments have evolved that target SMN2 either by activating the promoter or 
increasing exon 7 inclusion during splicing [6]. Histone deacetylase inhibitors (HDACi) are 
pharmacologic compounds that aid in the decondensation of chromatin, which promotes gene 
expression, although non-specifically and at a global level. One such HDACi, sodium butyrate, 
increased exon 7 inclusion in a cell-based model and increased SMN levels in motor neurons of 
the spinal cord in SMA mice [60]. Valproic acid (VPA) and phenylbutyrate (PBA) HDAC 
inhibitors only modestly increased SMN in patient fibroblasts in vitro, and the extent of this 
increase was dependent on SMN2 copy number [61, 62]. Unfortunately, both of these compounds 
provided minimal effectiveness in clinical trials [6, 63-65]. HDAC inhibitors, Trichostatin A 
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(TSA) and suberoylanilide hydroxamic acid (SAHA) both significantly extended survival in 
SMA mice [66, 67]; and TSA treatment supplemented with nutritional support increased survival 
even further [68]. In addition, administration of sodium butyrate or SAHA in the drinking water 
of gestating female mice beginning on embryonic day 15, led to a decrease in disease severity of 
SMA progeny or amelioration of embryonic lethality, respectively [60, 67]. Interestingly, HDAC 
inhibitors seem to provide general neuronal protection in a manner independent of SMN, 
although it is not clear as to how this occurs. However, it has been proposed that this 
neuroprotection may be due to the inhibition of atrogene pathways which normally mediate the 
breakdown of muscle proteins in a myogenin-dependent manner [69]. 
SMN expression has been shown to be in part, regulated via the STAT5 pathway [70, 
71]. Prolactin, a known activator of this pathway, is a hormone and canonically penetrates the 
blood-brain barrier. Farooq et al. (2011) demonstrated that increased SMN expression and 
protein levels in vitro and in vivo could be attained, along with a significant extension of survival 
in SMA mice following prolactin administration. Although prolactin did not provide a robust 
rescue, it may be possible to use this treatment as a supplemental therapy to maximize effects of 
other regimens. 
Another strategy implemented to modulate SMN2 splicing is through the use of nucleic 
acids to promote exon 7 inclusion [6]. Antisense oligonucleotides (ASOs) and bifunctional 
RNAs [72-79] perform this function in a manner similar to RNA interference; using a short 
stretch of nucleotides (e.g. 20mer) to bind a specific RNA target sequence with a high degree of 
specificity. For example, as in the case of SMA, an ASO may be designed to target a splice 
repressor that normally promotes exon 7 exclusion; in this way, inhibition of a repressor would 
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favor the retention of exon 7 [77]. ASOs are modified for stability and reduced nuclease activity, 
affording them an extended half-life [6]. Bifunctional RNAs are used in a similar manner only 
they perform a dual function; they contain a RNA sequence domain complementary to the RNA 
target sequence and an additional untethered sequence which serves as a binding domain for 
specific splicing factors [77]. These recent advances in RNA-based therapeutics have greatly 
accelerated a new wave of research [6, 80] that can embrace the limitless possibilities and 
versatility of RNA, making this therapy amenable to the study of innumerable diseases. 
A very promising new compound produced by ISIS Pharmaceuticals is currently being 
investigated in a multiple-dose Phase 2 study (ClinicalTrials.gov, Identifier: NCT01839656); 
ISIS-SMNRx
 
 is an ASO designed to modulate SMN2 splicing to promote exon 7 inclusion. This 
therapeutic is injected intrathecally into the cerebrospinal fluid and remains in the central 
nervous system (CNS) for an extensive amount of time. However, the current Phase II study, 
which is expected to be completed in 2014, is addressing the question of whether larger doses are 
safe and can be well tolerated. A Phase III study is anticipated to begin in 2014. 
Gene Therapy for Spinal Muscular Atrophy 
Gene therapy provides the most robust rescue in SMA mice to date and has been utilized 
extensively by many laboratories. SMA is well suited for viral-based gene delivery because the 
disease is monogenic and the SMN cDNA is small enough to be packaged into a viral vector. 
Adeno-associated virus (AAV) serotype 9 has broad tissue tropism with a high transduction rate 
into motor neurons, and as SMA is a motor neuron disease, it is appropriate that this serotype be 
utilized to specifically target the CNS [81-83].  
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Using GFP as a reporter, it has been demonstrated that systemic delivery of AAV9-GFP 
by intravenous injection, results in extensive transduction in motor neurons of neonatal mice 
(60%), but was limited in adult mice in which astrocytes were the predominant target [84]. This 
suggests that AAV9 was able to permeate the CNS of neonates where the blood-brain barrier 
(BBB) is not yet fully formed as opposed to adult mice in which the BBB has fully developed. 
Two explanations have been proposed to further elucidate this observation [84]. First, is the fact 
that astrogenesis occurs in mice during the first two weeks of the postnatal period and second; it 
is possible that astrocytic projections make contact with vascular endothelia and thus, capture 
most of the virus particles before they are able to make their way past, to the motor neurons. The 
BBB poses an obstacle for viral gene delivery because the endothelial cells separating the 
vasculature and cerebrospinal fluid (CSF) form a tight barrier through which many molecules 
cannot pass. However, with the advent of double-stranded self-complementary AAV vectors 
(scAAV) in which the second strand synthesis step is bypassed and more specifically, the 
generation of the scAAV9 vector, it was demonstrated that the efficiency of adult CNS 
transduction could be increased [82]. Intravenous administration of scAAV9-GFP not only 
provided robust transduction of neonatal motor neurons (likely due to the accelerated onset of 
expression obtained with scAAV as opposed to AAV), but also transduced up to 28% of motor 
neurons in adult mice [82]. Furthermore, following administration in neonates, GFP-positive 
cells were detected in the CNS as well as non-CNS tissues, in contrast to an intraperitoneal (IP) 
injection which resulted in only a few transduced cells in the CNS, and to an even lesser extent 
following intramuscular injection [82]. Once the potential for achieving motor neuron 
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transduction in vivo was demonstrated, multiple laboratories applied this technology to SMA and 
used this vector to overexpress SMN in SMA mouse models. 
 
Therapeutic Window for SMA Intervention     
Route of delivery and timing of administration are two important decisions to consider 
when applying gene therapy to SMA because variations of both lead to distinguishable results. 
Initial studies implementing scAAV9 to overexpress SMN, administered the virus by intravenous 
injection (IV) between the day of birth (P0) and postnatal day 2 (P2). This mode of intervention 
completely ameliorates disease progression in the SMNΔ7 model but does not have the same 
effect on the more severe SMN2 mice, although it does extend their survival significantly. 
SMNΔ7 mice are born presymptomatic and live on average, 14 days however; when injected 
with scAAV9-SMN into the facial vein during this early postnatal period, these mice gained 
significantly more weight that untreated controls and lived a normal lifespan (>200 days) [81, 
85]. On the contrary, disease progression could not be ameliorated in the SMN2 model but the 
animals did gain significantly more weight than control SMA mice, and they lived on average, 
100% longer than controls [86]. 
Prolonging SMN induction proves to be less efficient. Only a modest benefit was 
achieved when scAAV9-SMN was administered intravenously on P5, extending survival from 
15 to 30 days; significantly less than what the same injection provides on P1 or P2, in which 
mice lived over 250 days [81]. Further delay of treatment until P10 provided no benefit, 
indicative of a narrow window of opportunity for therapeutic intervention to have an effect.  
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 In parallel, this decreased therapeutic benefit from prolonging intervention was also 
described in the case of ASO technology. Porensky et al. (2012) used an ASO that modulates 
SMN2 splicing to increase exon 7 inclusion [87]. Direct CNS administration on P0 provided a 
robust rescue in SMNΔ7 mice. Survival was extended from 15 to 100 days, SMN levels were 
significantly increased and SMN expression was successfully restored to motor neurons with 
high expression in the cytoplasm, as well as the formation of gems within the nucleus. Similar to 
previous reports describing scAAV9-SMN intervention, administration at a later time point (P4) 
decreased the efficiency of this ASO therapeutic, by providing only a modest extension in 
survival (41 days) when mice were injected by ICV, and significantly less when injected by IV 
(21 days) [87].  
 In 2012, a detailed analysis of the differential effects observed between ICV and IV 
administration was reported for both the symptomatic SMN2 mice and the presymptomatic 
SMNΔ7 mice [85, 86]. ICV or IV delivery of 2x1011
86
 viral genomes (v.g.) into symptomatic mice 
on P1 significantly extended survival from an average of 5 days to 17 and 10 days, respectively. 
SMN was significantly increased in the brain and spinal cord of both groups. Muscle fiber area 
was only slightly increased in the ICV group but not in the IV injected mice [ ]. However, a 
more substantial benefit was observed when intervention was administered before symptoms 
appeared. In the SMNΔ7 model, delivery of 2x1010
85
 v.g. on P2 resulted in a complete rescue 
when delivered either by ICV or IV, with sufficient SMN restoration in the CNS, as well as 
restoration of motor function [ ]. As this treatment did not provide a full rescue in SMN2 mice 
as it did in SMNΔ7 mice, this further supports the indication of a therapeutic window in which 
treatment must be administered before the disease progresses too far. Restoration of SMN once 
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overt symptoms are occurring may not be the best method for treating the disease at this point, 
meaning that this therapy may need to be adapted or perhaps a combinatorial therapeutic regimen 
may prove a more effective means of halting the disease once it has progressed to advanced 
stages. 
 Further elucidation of this prospective therapeutic window was provided in reports of 
which an SMN-inducible mouse model was used. In order to mimic human SMA in mice, Lutz 
et al. (2011) created a mouse line in which the endogenous Smn gene was designed to behave 
like human SMN2 by replacing murine Smn exon 7 and 8 with a cassette consisting of human 
SMN2 exon 7 and 8. Additionally, an inverted and silent copy of mouse Smn exon 7 was placed 
within SMN2 in the intron between exon 7 and 8. The generated hybrid allele contained also, 
loxP sites flanking both exon 7s. This allowed conditional and irreversible activation by cassette 
inversion to express functional, full-length protein at wild-type levels within 48 hours of 
tamoxifen administration. When they turned on SMN expression during embryonic development 
on embryonic day 6 (E6), they observed a complete restoration to a wild-type phenotype [88]. 
This is interesting because throughout most studies that utilize the SMNΔ7 model, the treated 
mice always have a smaller, weaker overt phenotype compared to unaffected mice, although they 
do often gain significantly more weight than untreated controls. SMN induction following 
tamoxifen administration on P4 or P6 provided a substantial rescue but P8 induction only slightly 
enhanced survival while P10 did not provide any benefit [88]. 
 Furthermore, Le et al. (2001) developed another SMA inducible mouse model where 
SMN is expressed only upon administration of doxycycline. The SMN construct here consists of 
two minimal cytomegalovirus (CMV) promoters and a tetracycline response element (TRE). 
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This dual reporter system, upon doxycycline activation, drives SMN and luciferase expression 
[89]. This inducible model took three days for an increase in SMN to be observed following 
induction, however, this report provided similar results as the Lutz group [90]. Induction at E13 
or P0/P1 provided a complete rescue, with mice living over 200 days however; the benefit was 
not as substantial as the rescue Lutz et al. (2011) described when induction began on E6. As 
expected, induction on P2 (SMN increase detectable at P5) had  less dramatic effect where all the 
mice except one, lived on average 25 days, with the exception living to 151 days. Also, mice 
induced on P0/P1 in which SMN expression was turned off at P28, in general lived only a month 
following SMN removal, with the exception of one mouse that lived over 8 months. Outliers 
such as these two above are common occurrences in these types of studies and this may be due to 
intrinsic genetic or epigenetic factors or overall pathological differences between mice [89].  
 Overall, early restoration of SMN provides the most beneficial outcome whereas delayed 
intervention substantially diminishes the efficacy of this therapeutic modality. Route of 
administration also changes the outcome, where systemic and direct CNS injections provide the 
best results when implemented in a timely manner.  
 It is interesting to compare the studies involving direct CNS administration to the report 
by Hua et al. (2011) who demonstrated that ASO delivery into the periphery alone, increased 
survival significantly compared to direct CNS administration. This might suggest that peripheral 
tissues that succumb to SMN depletion may have a negative effect on downstream targets, 
perhaps some in the CNS, and that is perhaps why Hua et al. (2011) observed these results. 
However, it is difficult to determine as of now because the systemic dose that was injected was 
much higher than the dose administered to the CNS [91]. 
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Timing of therapeutic administration for SMA has shown to be of utmost importance, 
where intervention at the presymptomatic stages has the most beneficial outcome. It is still 
unclear why this is the case but one explanation highlights the importance of the target cell 
population. There may be a window in which motor neurons are no longer able to respond to 
treatment. Perhaps they have degenerated to a point where no matter how much SMN is pumped 
into them, it may not fix the damage that has already progressed. It is also possible these cells 
lose specific communication signals and are no longer able to be transduced by the virus. 
Another limit to this intervention is the mode of administration. As scAAV9 readily transduces 
cells in the CNS when administered intravenously in neonates, this effect is diminished when 
intervention is delayed after birth. This may possibly be due to complete closure of the BBB or 
other hemodynamic alterations in which the virus is not sufficiently transported into the CNS.  
Furthermore, there is evidence of viral entry by retrograde transport from the muscle; 
however, the reports on direct intramuscular injection do not conclusively support this [92]. It is 
still debated whether systemic or direct CNS injection is the best route of delivery as there are 
two schools of thought about this. Some researchers hold true to the idea that SMA is a motor 
neuron disease and that SMN replacement in motor neurons is sufficient to halt the disease 
whereas; the other side of the argument highlights that motor neuron induction alone, does not 
completely ameliorate all symptoms [33]. Replacement of SMN solely in motor neurons does not 
preserve the integrity of all tissues as is evident in the numerous studies that report on the sudden 
death often observed of a sub-group of treated mice [93]. This suggests that SMA affects 
multiple organ systems and supports the idea of a multifactorial intervention scheme. 
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CHAPTER TWO: SPINAL MUSCULAR ATROPHY - DISEASE DEVELOPMENT AND 
THERAPEUTIC WINDOW USING SCAAV9-SMN IN THE DELTA7 MOUSE MODEL 
 
Introduction 
SMA is well suited for therapeutic intervention because the disease is monogenic, the 
patient population is homogenous and humans possess the important disease-modifying gene, 
SMN2. Strategies to circumvent SMA progression focus on SMN1 gene replacement or the 
alteration of SMN2 splicing. Gene therapy using self-complementary adeno-associated virus, 
serotype 9 (scAAV9) to deliver SMN, either systemically or directly into the CNS, has shown 
the most promising results for rescuing SMA mice when administered before the therapeutic 
window closes. 
Previously, it has been demonstrated in a severe SMA mouse model, that SMN induction 
as early as E6 completely ameliorates the disease phenotype [88]. However, administration of 
scAAV9-SMN between P0 – P2 provides a near complete rescue but does not correct vascular 
side effects such as tail and ear necrosis; and additionally, peripheral organ defects are often 
observed [85, 88]. Furthermore, slight delay of therapeutic intervention results in only a modest 
rescue, and an extended delay provides no benefit. Utilizing the well characterized SMNΔ7 
model, we performed a systematic analysis to determine the effects of delaying scAAV9-SMN 
administration. We injected each mouse with a single injection of 1x1011 viral genomes (v.g.) 
scAAV9-SMN at a single time point, P2 through P8. Early SMN induction provided the most 
benefit, whereas, injection at later time points decreased the efficacy of this therapy. All treated 
mice lived significantly longer, but SMN induction at the earliest time point (P2) provided the 
most robust rescue with the fewest early deaths. Treated mice gained weight, demonstrated 
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restored motor function and exhibited SMN protein induction in the CNS and periphery. 
Treatment at the various time points resulted in a range of phenotypes observed within the mice, 
but is was evident that the earliest administration provided the best rescue, while delaying 
intervention decreased the effectiveness. 
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Materials and Methods 
 
Animal Handling and Genotyping 
All animals were housed and treated with respect to the guidelines of the Animal Care 
and Use Committee at the University of Missouri and in accordance with the regulations defined 
in the “Guide for the Care and Use of Laboratory Animals,” (National Research Council, 2011). 
The SMN delta7 (SMNΔ7) mouse model was utilized for these experiments. SMNΔ7 
mice are null for mouse Smn and contain two copies of both transgenes, human SMN2 and the 
cDNA coding sequence for SMNΔ7. Mice heterozygous for mSmn (Smn+/-;SMN2+/+;SMNΔ7+/+) 
were purchased from the Jackson Laboratory (Bar Harbor, Maine, USA; stock 005025) and were 
bred to generate mSmn knock-out mice (Smn-/-;SMN2+/+;SMNΔ7+/+) used in these experiments. 
Heterozygous (Smn+/-;SMN2+/+;SMNΔ7+/+) mice are used throughout all the experiments as 
unaffected positive controls and untreated SMA (Smn-/-;SMN2+/+;SMNΔ7+/+) mice were used as 
negative controls. On their day of birth, postnatal day 1 (P1), each mouse was numbered using a 
non-toxic, permanent marker for individual identification, and remarked each day after, until the 
presence of fur in which they were then marked permanently with fuchsine dye. The distal tip of 
the tail was removed, ~1 mm, with sharp, heated scissors to aseptically remove the tail tissue and 
cauterize the wound. Genotyping was carried out by lysing the tail tissue in 75 µl of alkaline 
solution (25 mM NaOH, 0.2 mM EDTA) for 30 minutes at 95°C followed by neutralization in 75 
µl of a TRIZMA-HCl solution (40 mM TRIZMA-HCl) and incubation on ice. Polymerase chain 
reaction (PCR) conditions were as follows: 95°C 2 minutes, 30 cycles (95°C 15 seconds, 68°C 
90 seconds), 68°C 10 minutes. Primers were used to amplify the mSmn wild-type allele, forward 
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(5’-TCTGTGTTCGTGCGTGGTGACTTT-3’) and reverse (5’-CCCACCACCTAAGAAAGCCTCAAT-3’) 
and the lacZ mSmn knockout allele, forward (5’-CCAACTTAATCGCCTTGCAGCACA-3’) and 
reverse (5’AAGCGAGTGGCAACATGGAAATCG-3’). 
 
Virus Production  
scAAV9-SMN viral vector was produced as described previously [86].  HEK293T cells 
were triple transfected in the presence of polyethyleneimine (PEI) (1mg/ml), pH 5.0 [94]. The 
scAAV plasmid was constructed to express the open reading frame of human SMN1 cDNA 
(NCBI accession number NM_000344) under the control of the chicken β-actin promoter. 
Following media change and cell collection at 24 hours and 48 hours post-transfection, 
respectively, scAAV9-SMN viral vector was purified using three cesium chloride density-
gradient centrifugation steps and dialyzed with HEPES buffer.  
 
Real-time PCR (qPCR) 
Quantification of viral genomes was performed using SYBR® Green and primers to 
amplify the chicken β-actin promoter region, forward (5’-CCGGTGGTGGTGCAAATCAAAGAA-3’) 
and reverse (5’-AGCAGAAGTAACACTTCCGTACAGGC-3’). The absolute quantitation method 
using a standard curve was utilized on the Applied Biosystems® 7500 Real-Time PCR System 
using Applied Biosystems 7500 Sequence Detection Software version 1.3. Viral fractions were 
diluted 1:1000 and the PCR cycle was as follows: 50°C 2 minutes, 95°C 10 minutes, 40 cycles 
(95°C 15 seconds), 60°C 1 minute. A standard curve was obtained using serial dilutions of the 
transgene-containing plasmid (1010-105) to calculate melting curves of each sample. The viral 
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fractions containing the highest titer were dialyzed with HEPES buffer (100 mM NaCl, 20 mM 
HEPES).  Following dialysis, qPCR was performed to obtain the final titer of the virus-
containing solution to be used for injections into the mice. 
 
Intracerebroventricular Injection of scAAV9-SMN or scAAV9-GFP 
Intracerebroventricular (ICV) injection was performed on neonates to administer 
scAAV9-SMN therapy directly into the CNS. Mice were administered a single injection of 
1x1011
 
 v.g., on one of the following days, P2 through P8. Briefly, a glass-pulled needle was 
inserted through the frontal plate (lateral to the metopic suture and rostral to the coronal suture) 
into the left or right ventricle of the neonatal mouse to deliver a 5 µl bolus of viral vector. 
Unaffected animals were injected with scAAV9-GFP on P2 or P7 and non-injected mice were 
used as a negative control. 
Phenotypic Assessment  
All treated and untreated mice were monitored daily to evaluate survival, weight gain and 
motor function as assessed by the time to right test. The time to right test consists of placing a 
mouse on its back and determining the time it takes for them to right themselves onto all four 
paws. A mouse unable to right within 30 seconds is considered to have failed the test for that 
day. 
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Tissue Collection  
 Tissues were collected on P11 for all mice treated with scAAV9-SMN and on P6 or P11 
for those injected with scAAV9-GFP.  To harvest the tissues, mice were anesthetized using 
isofluorine followed by cervical dislocation. Brain, spinal cord, skeletal muscle, heart, kidney, 
liver, and spleen were collected and immediately flash-frozen in liquid nitrogen for those tissues 
used for protein analysis or submerged in 4% paraformaldehyde if used for histological 
examination of GFP.  
 
Western Blot Analysis 
For the SMNΔ7 mouse Western blots, tissues were collected at selected time points and 
immediately frozen in liquid nitrogen. Tissue samples were placed at -80oC until ready for 
analysis. Roughly 100 mg of tissue was homogenized in JLB buffer (50 mM Tris-HCl pH 7.5, 
150 mM NaCl, 20 mM NaH2(PO4), 25 mM NaF, 2 mM EDTA, 10% glycerol, 1% Triton X-100, 
and protease inhibitors (Roche, Indianapolis, IN, USA). Equal amounts of protein were separated 
on 12% SDS-PAGE gels. SMN immunoblots were performed using a mouse SMN specific 
monoclonal antibody (BD Biosciences #610647, San Jose, CA, USA) diluted 1:2000 in 1% dry 
milk in TBST (Tris-buffered Saline Tween20 (10mM Tris-HCl, pH7.5, 150mM NaCl, 0.2% 
Tween20) and a secondary anti-mouse HRP-conjugated secondary antibody (1:10,000). Blots 
were visualized by chemiluminescence on a Fujifilm imager LAS-3000 and the corresponding 
software. To verify equal loading, the membranes were then stripped using β-mercaptoethanol 
for 30 minutes at 50°C and re-probed with anti-β-actin rabbit antibody (Sigma #A5060, St. 
Louis, MO, USA)  diluted 1:2000 and anti-rabbit HRP secondary antibody (1:10,000). Western 
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blot analysis was performed in triplicate and representative blots are shown. Probes were 
visualized by chemiluminescence using the Pierce SuperSignal Pico reagents. 
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Intracerebroventricular Injection of scAAV9-SMN Increases Survival of SMNΔ7 Mice   
On average, mice from all treatment groups lived significantly longer than non-injected 
animals however; there was variability within groups (Figure 2.1, 2.2, 2.3). Mice injected on P2 
experience no early deaths (all mice lived past 130 days) and they lived the longest with an 
average lifespan of 187 days and a median survival of 204 days. The early deaths of the P3 and 
P4 injected groups occurred on days 47 and 50, respectively. The P3 injected group lost another 
subset of the population between days 60 and 100 but the remaining three mice lived past 150 
days (maximum 187 days). The average survival for the P3 group was 102 days with a median 
lifespan of 75 days. Mice in the P4 injected group steadily decreased in numbers with the oldest 
animal living 211 days; and the average for the group was 141 days with a median lifespan of 
167 days. In the P5 injected group, seventy percent of the treated mice died between days 22 and 
42, with the remaining three mice living 152, 165 and 211 days. The average and median 
survival for the P5 group was 76 and 37 days, respectively. Sixty-two percent of the mice in the 
P6 group died between 20 and 35 days while the remaining three mice lived 50, 184 and 211 
days; the average and median for the group were 73 and 34 days, respectively. Within the P7 
injected group, eighty percent of the animals died between days 21 and 34, while the oldest 
animal survived 70 days. Mice from the P7 injected group lived on average, 30 days with a 
median survival of 28 days. The P8 injected group had a significant extension in survival, 
compared to non-injected animals, although this was not as substantial as the survival extension 
exhibited by the earlier-injected mice (Figure 2.3). Both the average and median survival values 
for mice in the P8 group were 18 days. A high degree of variability is observed with the survival 
data of each group treated at median time points P3 through P7 (Figure 2.4). Overall, mice 
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injected with scAAV9-SMN at earlier time points had a greater extension in survival compared 
to mice injected at later time points; and mice from all groups lived significantly longer than 
non-injected controls which lived on average, 13 days with a median survival of 14 days. 
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Figure 2.1. ICV injection of scAAV9-SMN increases the survival of SMNΔ7 mice when 
administered at early time points. Kaplan-Meier survival curve of untreated SMNΔ7 mice and 
those injected with 1x1011
 
 v.g. of scAAV9-SMN on a single day P2-P8.  
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Figure 2.2. SMNΔ7 mice injected at early time points live longer on average compared to mice 
injected at later time points. All treated SMA mice lived significantly longer than non-injected 
controls (Refer to p-table, Figure 2.3). 
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Figure 2.3. P-table demonstrating statistically significant differences in average survival of mice 
in the treatment and non-treatment groups. All treated mice lived significantly longer than non-
injected controls. P-values were calculated using the logrank Mantel-Cox test and the table 
illustrates the significance in survival between groups. NI = non-injected. (n.s. no significance, * 
p ≤0.05, ** p ≤0.01, *** p ≤0.001, **** p ≤0.0001).  
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Figure 2.4. There is a high degree of variability in survival observed within each group of mice 
injected at the median time points. For each treatment group, the line represents the average 
survival for the group and the data points represent the minimum, median and maximum survival 
within each group. There is a higher degree of variability observed within groups P3 through P7, 
while the P2, P8 and the non-injected groups display less variation in survival. 
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Weight Increase Observed in All Treated Groups   
Weight gain was analyzed as the average weight for a given group across days (Figure 
2.5) and also as the average percent weight gained from birth to peak weight (Figure 2.6, 2.7). At 
birth, all SMA pups and unaffected pups are similar in weight and there are no obvious 
phenotypic differences until around day 7 (Figure 2.8). However, by day 11 all treated mice 
weighed significantly more than non-injected animals. Even the late injected mice (P7 and P8) 
weighed significantly more, although this difference was not as substantial as the difference 
observed between early injected mice and the non-injected controls. Compared to non-injected 
animals, mice injected on P3 weighed significantly more by day 7, those of P4, P5 and P8 were 
significantly higher by day nine, group P2 by day 10 and groups P6 and P7 were significantly 
higher than non-treated animals by day 11. Around day 10, the P8 and non-injected mice reach a 
plateau and their weight declines from thereon. By day 14 the P8 injected group weighed 
significantly less than mice from all other treatment groups. At day 17 an emergence of two 
groups within the weight observations can be observed. The first group consisting of P2, P3 and 
P4 have similar weight gain and as a group diverge from a second cluster consisting of P5, P6 
and P7. 
All treated animals exhibited a significantly higher percent weight gain from birth to their 
peak weight, compared with non-treated animals; the significance between these groups varied 
(Figure 2.6 and 2.7). Animals injected on P2, P3 or P4 displayed similar weight gain from birth 
to peak, and there was no significance when compared with each other. Similarly, animals 
injected on P5, P6 or P7 had comparable percent weight gain and also did not show significance 
when compared to one another. Comparison of either group P2, P3 or P4 with any of group P5, 
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P6 or P7 was significant; for all comparisons p ≤ 0.0001 except P4 compared with P5 or P6 (p ≤ 
0.001). Mice in the P8 group gained significantly less weight than mice in groups P2 through P6, 
but not P7. All treated mice gained weight following treatment with scAAV9-SMN. 
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Figure 2.5. SMNΔ7 mice treated with scAAV9-SMN gain weight throughout their lifespan. The 
average weight per group is plotted across days for the surviving animals in each cohort. ni
 
 = 
initial number of animals in each group. 
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Figure 2.6. Percent weight gained from birth to peak. SMNΔ7 mice (Smn-/-;SMN2+/+;SMNΔ7+/+) 
treated with scAAV9-SMN gain more weight than non-injected controls. Percent weight gained 
from birth to peak for all treated animals is significantly higher compared to non-injected mice 
(Refer to p-table, Figure 2.7). Weight gain for unaffected heterozygous (Smn+/-
;SMN2+/+;SMNΔ7+/+
 
) littermates is shown here to provide a visual comparison of treated mice to 
healthy unaffected individuals; however, these data were not used for statistical comparisons. 
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Figure 2.7. P-table demonstrating statistically significant differences in average weight gained 
from birth to peak all mice in the treatment and non-treated groups. SMNΔ7 mice treated with 
scAAV9-SMN gain significantly more weight than untreated littermates. Student’s t-tests were 
performed to compare the average percent weight gained from birth to peak between groups. 
(n.s. no significance, * p ≤0.05, ** p ≤0.01, *** p ≤0.001, **** p ≤0.0001). 
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Figure 2.8. Representative images of SMNΔ7 mice. A) Phenotypic differences are not apparent 
at birth and the pups of the various genotypes cannot be distinguished by observation. WT 
(Smn+/+;SMN2+/+;SMNΔ7+/+), HET (Smn+/-;SMN2+/+;SMNΔ7+/+) and SMA (Smn-/-
;SMN2+/+;SMNΔ7+/+
 
). B) At 9 days old, it can be readily observed that the pup injected at the 
earliest time point (P2) has gained weight comparable to the unaffected heterozygous littermate; 
and the pups injected at the latest time points (P7 and P8) are slower to gain weight. 
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Early Treatment Improves Motor Function in Mice Injected with scAAV9-SMN  
Mice have the propensity to right themselves onto all four paws immediately after being 
placed on their back; and young, healthy neonates achieve this strength within the first week of 
life [95]. Mice treated with scAAV9-SMN at the different time points exhibited differences in 
motor function, as assessed by the time to right test. To assess the animals’ strength, a mouse 
was placed on its back and the time it took them to right themselves was measured. A mouse 
unable to right itself within 30 seconds was recorded as having failed the test for that trial. This 
test was repeated daily throughout the lifespan of all treated mice. Over time, a greater 
percentage of animals from groups P2 through P7 gained the ability to right themselves however, 
this was not the case for the non-injected animals and those injected at the latest time point, P8 
(Figure 2.9). Untreated SMNΔ7 mice display weakness beginning around day seven however; 
some mice are inherently stronger than others. Therefore, it is not uncommon to observe mice 
from the late injection and non-injected groups performing the time to right test on various days. 
A high percentage of mice injected on P2, P3, and P4 (80%, 56%, 56%, respectively) gained the 
ability to right themselves by day eleven, and they maintained this ability throughout the testing 
period and into adulthood. In contrast, a lower percentage of treated mice from the median time 
points P5 and P6 (20% and 22%, respectively) are able to right themselves by day 11; but the 
ability to right does increase for these groups around day 14 (70% and 75%, respectively), and is 
maintained throughout adulthood. Animals from the P7 group display variability in righting 
themselves, with few animals turning during the first few days of the testing period. Although 
these animals do not live until adulthood (Avg. 30 days, Figure 2.2), they all eventually gain and 
maintain the ability to right throughout their shorter lifespan. Only five of the ten mice in the P8 
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injected group were ever able to right themselves, and four of them lost this ability 2-3 days prior 
to death. As expected, mice of the non-injected group performed poorly on this test and only two 
out of the ten mice gained the ability to right themselves.  
Of the mice that are able to right themselves, the early-injected animals tended to turn 
over faster than those injected at later time points and the mice in the non-injected group. Figure 
2.10 displays the average time to right for each group on days 6-24. During the second week of 
postnatal development P2 and P3 reduce their performance time substantially afterwards which 
P2 is able to right immediately whereas the P3 group maintains an average time of 4 seconds. 
The P4 group steadily reduces its average time to right during the second week and is also able to 
turn over immediately starting on the third week. The P5 and P6 injected mice follow a similar 
pattern but with less impact; these mice are able to turn over immediately but not until they are 
into their third week. Mice in the P7 group were slower to gain this ability and did not perform 
well until into the third week however, they finally decreased their average turning time which 
they maintained until their death. Only a few animals in the P8 and non-injected groups were 
able to turn, but they were slow to do so. Motor function varied for mice on a given day, both 
between groups and within groups (Figure 2.11). However, a trend is apparent between groups of 
mice injected at different time points, and those injected at earlier time points perform better on 
the time to right test and are able to maintain this ability throughout their lifespan. 
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Figure 2.9.  Percentage of animals able to right themselves. Assessment of motor function shows 
that SMNΔ7 mice treated with scAAV9-SMN at earlier time points perform substantially better 
on the time to right test. Animals treated at early time points gain the ability to right themselves 
prior to animals injected at later time points. 
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Figure 2.10.  Average Time to Right for SMNΔ7 mice treated with scAAV9-SMN. Mice 
injected at later time points exhibit less muscle control and turn slower than mice injected at 
earlier time points. 
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Figure 2.11.  Individual performance of the time to right test on day 14. A) At two weeks, earlier 
treated animals perform better on the time to right test compared to those injected at later time 
points. B) There is a high degree of variability observed within groups; where some mice are 
able to right themselves more quickly than others, and some animals never gain the ability to 
turn. Mice able to right themselves within 0-5 seconds was recorded as a success, 6-24 seconds 
demonstrated average performance and those from 25-30 seconds were considered failures for 
this illustration. 
0% 
20% 
40% 
60% 
80% 
100% 
P2 P3 P4 P5 P6 P7 P8 Non-Injected 
Success 40% 33% 22% 10% 13% 11% 0% 0% 
Average 50% 44% 33% 60% 50% 22% 11% 0% 
Failure 10% 22% 44% 30% 38% 67% 89% 100% 
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SMN Protein Induction  
Increased SMN protein was observed in animals treated with scAAV9-SMN (Figure 
2.12). SMNΔ7 mice were injected on P2 or P7 and their tissues harvested on day eleven. The 
increased SMN expression observed in P2 and P7 injected mice compared to unaffected mice 
was due to the dose of viral particles resulting in higher levels of SMN compared to endogenous 
expression levels. Furthermore, low levels of SMN observed in the non-injected animals was 
expected because these mice harbor only two copies of human SMN2 and only 10% of 
transcripts from each copy of the gene produce functional SMN protein. Mice injected on P2 
exhibited significantly higher SMN levels in the brain compared to P7 injected mice (p = 
0.0037) and P2 expressed significantly more SMN compared to the non-injected mice (p = 
0.0032). P2 and P7 injected animals expressed significantly more SMN in the spinal cord 
compared to non-injected animals (p = 0.0003 and p = 0.0082, respectively) and the P2 group 
expressed significantly more protein than P7 (p = 0.0007). Robust induction was also observed 
in peripheral organs such as the heart. In the heart tissue both P2 and P7 injected animals express 
significantly more SMN than non-injected controls (p = 0.0006 and p = 0.0079, respectively). 
Furthermore, scAAV9-SMN administration on P2 resulted in significantly higher SMN levels in 
the heart compared with the P7 group (p = 0.0023). Protein induction on P2 or P7 greatly 
increased protein levels in the brain, spinal cord and heart. 
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Figure 2.12. SMN protein induction is evident in SMNΔ7 mice injected at early and late time 
points. In the brain, SMN was upregulated significantly in the P2 mice compared to both the P7 
and non-injected groups, but there was no significance observed between P7 and the non-injected 
group. There was robust expression observed in the spinal cord where both P2 and P7 injected 
mice expressed significantly more protein than non-injected controls and the P2 group exhibited 
a significantly higher level of protein than the P7 group. In the heart, both the P2 and P7 injected 
mice exhibit a significant induction of SMN. The fold difference of the Western blots (n = 3 for 
each group) is shown as the average SMN/actin ratio after normalization of SMN to β-actin. 
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To answer the question of whether the robust expression observed in the P2 group 
compared to P7 was due to the fact that the virus was expressing five days longer in the P2 
animals, as tissues from both groups were harvested on day eleven, we also harvested tissues 
from P2 injected animals on day 6 to account for this discrepancy (Figure 2.13). 
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Figure 2.13. Robust SMN expression is observed four days post therapeutic P2 administration, 
confirming that equal protein induction intensity is consistent with the same time frame as P7 
administration.  
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Peripheral Distribution of scAAV9-SMN and Transduction Analysis  
To determine the extent to which scAAV9-SMN traverses the BBB and is distributed 
throughout the periphery we utilized the scAAV9-GFP vector to observe virus dispersion. 
Unaffected mice were injected with scAAV9-GFP on P2 or P7 and the heart, liver, spleen and 
kidney tissues were harvested on day six or day eleven (Figure 2.14). Results confirm that 
scAAV9 is well distributed throughout the periphery with especially strong GFP expression in 
the liver and heart tissues. 
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Figure 2.14. Unaffected mice injected with scAAV9-GFP exhibit substantial GFP expression in 
the periphery. In animals injected on P2, a stronger visualization was present throughout all 
peripheral tissues whereas, in P7 injected animals GFP was expressed the strongest in the liver. 
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Discussion 
Timing of therapeutic administration is critical for many diseases, and especially for 
SMA. The majority of infants not diagnosed at birth present with acute respiratory failure within 
the first year. By this time, the patients are severely compromised, whereas, an early diagnosis 
would lead to proper nutritional, therapeutic and even respiratory support, which would improve 
the quality of life for SMA children.  Multiple reports have demonstrated that early intervention 
provides maximal benefit regardless of the mode of therapy: SMN replacement or modulation of 
SMN2 splicing. Restoring SMN pre- and post-symptomatically has led to complete or partial 
rescue of SMA mice when SMN is reinstated during embryonic or early postnatal development. 
Gene therapy using self-complementary adeno-associated virus, serotype 9 (scAAV9-
SMN), to replace SMN, has shown promising results in that it rescues the SMNΔ7 mouse model 
when administered within the correct time frame [81, 85]. As SMA is namely a motor neuron 
disease, the scAAV9 vector is efficient at transducing a large proportion of the target cell 
population. scAAV9-SMN administration to SMNΔ7 mice intravenously on P1 or P2 resulted in 
a full rescue (survival >250d) but delaying delivery until P5 decreased survival (median ~25d), 
and treatment on P10 had no effect [81]. Comparison of IV and ICV delivery show that route of 
administration plays a role in suppressing disease progression. In the severe SMN2 mouse model, 
ICV injection significantly extended the survival when compared with IV administration. In the 
SMNΔ7 model both injection routes resulted in a complete rescue but the ICV group 
experienced fewer early deaths [85, 86]. 
Transgenic mice harboring an inducible Smn allele have been generated to analyze 
temporal requirements of wild-type SMN levels. Early induction provides a more substantial 
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rescue compared to delayed induction, however, reinstatement during embryonic development 
(E6) completely ameliorates the disease phenotype.  
Antisense technology is utilized in SMA research to increase SMN protein levels by 
modulating SMN2 splicing. For example, use of antisense oligomers (ASOs) to block an intron 
splice silencer, ISS-N1, has been demonstrated to significantly increase full-length SMN2 
transcript levels and SMN protein in brain and spinal cord of the SMNΔ7 model [77, 87]. When 
the ISS-N1 ASO was administered by ICV injection on P0, the survival was extended from 15 to 
100 days. However, this group found that delaying delivery until P4 decreased the efficacy of the 
antisense therapy. Furthermore, IV administration on P0 resulted in survival comparable to the 
ICV group however, when delivery was delayed until P4, the IV injected group exhibited 
decreased survival. 
Taken together, these developments all support the idea that early intervention provides 
the maximal benefit for these modes of therapy. Here we have provided an in-depth analysis to 
investigate temporal requirements for SMN protein. Multiple time points during the postnatal 
period were chosen for analysis in which SMNΔ7 mice were injected with 1x1011
We observed that survival, weight gain and muscle strength correlated with timing of 
administration, and that mice injected at earlier time points lived longer, gained more weight and 
performed better on the motor function test than mice injected at later time points (Figure 2.15). 
All groups lived significantly longer than the P8 injected group and non-injected controls. 
Interestingly, mice injected on P2, P3 and P4 lived significantly longer (median: 157, 102, 142 
days, respectively) than those injected on P7 (median: 30 days). Despite the more modest effect 
 v.g. scAAV9-
SMN by ICV injection on a single day, P2 through P8.  
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observed with the P5 and P6 groups, each group had one mouse that lived past 200 days. 
Furthermore, groups P2, P3 and P4 did not differ significantly from each other in average weight 
gained, but mice from these earliest time points gained significantly more weight than all other 
treated mice, and all groups gained significantly more weight than mice from the non-injected 
group. Mice in all treatment groups (excluding P7) experienced significant weight gain 
compared to P8 injected mice. 
 We have performed a systematic analysis to investigate the effect of delaying therapeutic 
intervention using scAAV9-SMN with direct CNS administration. We utilized the SMNΔ7 
mouse model because it exhibits a severe SMA phenotype but lives 13 days [56], allowing 
enough time for investigation. Also, we used the self-complementary AAV vector because it 
transduces cells efficiently [82, 83], especially motor neurons [84], and induces expression 
relatively quickly (within 48 hours) [81]. SMN under the control of the chicken-β-actin promoter 
results in ubiquitous expression in the CNS and peripheral tissues [96]. In the investigation 
described here we assessed the phenotype of scAAV9-SMN treated mice using assays widely 
accepted in the field.  
 While others have demonstrated that IV injection of scAAV9-SMN provides a complete 
rescue in SMNΔ7 mice [81, 85], here we have performed ICV injection for direct delivery into 
the CNS, which provided the same result. However, delaying administration by the intravenous 
route provided a less substantial rescue [81] than when ICV administration was used, as we have 
described here. Furthermore, ICV delivery requires less virus to be used, which is translationally 
important for clinical consideration because virus production is costly. Perhaps in the case of 
SMA, a combination of virus delivery through both injection routes may demonstrate to be a 
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more efficient means of gene therapy since peripheral tissues are proposed to be affected by low 
levels of SMN as well as motor neurons. 
The idea that early intervention provides maximal benefit was further supported by the 
performance of these mice on the time-to-right test. By day 12, over 50% of mice in groups P2, 
P3 and P4 were able to right themselves whereas, only 10-30% of mice in the late injection 
groups could perform this test on day 12. Protein induction observed in CNS (robust) and 
peripheral (modest) tissues of treated mice lends us to suggest that the resulting extent of rescue 
observed in these mice is due, in part, to increased SMN levels in the CNS. Collectively these 
data support the importance of early therapeutic intervention and demonstrate that a narrow 
therapeutic window exists for which therapy must be applied to provide maximal benefit. 
This systematic investigation into the effect of delaying therapeutic intervention using 
scAAV9-SMN in the SMNΔ7 mouse model, has laid the foundation for others to elucidate the 
correlation between our observations of the overt phenotype of these mice with the molecular 
attributes involved in SMA pathogenesis. The results from this study support the idea that early 
intervention provides the maximal benefit for ameliorating SMA disease pathogenesis and this is 
clinically relevant as the field moves forward with designing therapeutics suitable for SMA 
patients in the near future. 
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Figure 2.15. Overt phenotype of P2 treated animal with scAAV9-SMN compared to unaffected 
and non-injected littermates.  
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CHAPTER THREE: CONCLUSIONS 
 
As described throughout the literature and clinical assessments, early therapeutic 
intervention provides maximum benefit in SMA patients and animal models. It is still unclear as 
to the direct progression of SMA disease pathology as to whether direct motor neuron 
degeneration causes SMA entirely or whether low SMN levels results in decline of peripheral 
organs and tissues which has a negative impact on motor neurons. Differential strategies have 
been implemented to further elucidate the biomolecular mechanisms occurring during SMA 
pathogenesis and each provides insight to answer these questions. 
We have provided a systematic and detailed analysis to determine the timing in which the 
therapeutic window of providing maximal benefit closes, in the context of SMA. While 
intervention at the earliest stages of postnatal development provides the most robust rescue with 
a significant extension of survival, we also observed a reduced degree of rescue in the mice 
injected at the later time points. While the majority of mice injected on P2 lived a full lifespan, 
only a small cohort of mice from treatment groups P3 through P6 exhibited a full extension of 
survival; with administration at P7 only providing a modest extension and P8 only provided 
minimal benefit. Furthermore, the variability observed in weight gain and motor function 
following treatment at the various time points suggests there is a progressive decline in these 
animals following initiation of symptoms and that in order for therapeutic intervention to provide 
a maximal benefit, intervention must be applied before disease symptoms progress too far. 
Whether the target cell population is lost or too impaired to respond to treatment during late 
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stages of the disease has yet to determined, but with the advancement in gene therapy and now, 
RNA-based therapy (ASOs), we will gain a better understanding of SMA disease progression. 
Endeavors focused to understand how low SMN levels translate into SMA disease 
pathology will be a critical component of future research in the SMA field. Development of 
intermediate SMA mouse models will aid in the elucidation of important biochemical and 
pathological aspects of SMA disease pathology.  These studies can lead to reevaluation of the 
timing effects and advance the investigations into the impact of delayed therapeutic intervention. 
Furthermore, a combination of pharmacologics and gene therapy may provide a more substantial 
effect upon therapeutic intervention [33].  
Importantly, investigation into the genetic and molecular basis of SMA has provided 
further insight on disease progression for other neurodegenerative disorders such as ALS and 
Alzheimer’s, Huntington’s and Parkinson’s disease. Furthermore, the field of SMA research has 
widely contributed to, as well as gained insight from, the multitude of other neuromuscular 
diseases such as Muscular Dystrophy. 
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